Recombinant human erythropoietin in patients on peritoneal dialysis
Bargman, J.
Peritoneal Dialysis International Journal of the International Society for Peritoneal Dialysis 9(4): 245-246
1989
ISSN/ISBN: 0896-8608 PMID: 2488375 Document Number: 331508
Document emailed within 1 workday
Related Documents
Aguilera, A.; Selgas, R.; Ruiz-Caravaca, M.L.; Bajo, M.A.; Cuesta, M.V.; Plaza, M.A.; Hernanz, A. 1999: Effects of recombinant human erythropoietin on functional and injury endothelial markers in peritoneal dialysis patients Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 19(Suppl 2): S161-S166Ksiazek, A.; Baranowska-Daca, E. 1993: Hematocrit influence on peritoneal dialysis effectiveness during recombinant human erythropoietin treatment in patients with chronic renal failure Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 13(Suppl 2): S550-S552
Lui, S.F.; Law, C.B.; Ting, S.M.; Li, P.; Lai, K.N. 1991: Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis Clinical Nephrology 36(5): 246-251
Boelaert, J.R.; Schurgers, M.L.; Matthys, E.G.; Belpaire, F.M.; Daneels, R.F.; De Cre, M.J.; Bogaert, M.G. 1989: Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 9(2): 95-98
Boratyńska, M.; Magott, M.; Szewczyk, Z. 1996: Treatment with human recombinant erythropoietin and nutritional status of patients on lon term dialysis Przeglad Lekarski 53(5): 402-405
Yamazaki, C.; Watanabe, Y.; Sakamoto, N. 1993: Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients Nihon Jinzo Gakkai Shi 35(11): 1233-1242
Kulzer, P.; Schaefer, R.M.; Krahn, R.; Schaefer, L.; Heidland, A. 1994: Effectiveness and safety of recombinant human erythropoietin (r-HuEPO) in the treatment of anemia of chronic renal failure in non dialysis patients. European Multicentre Study Group International Journal of Artificial Organs 17(4): 195-202
Morris, A.T.; Ronco, C. 2000: Erythropoietin therapy in peritoneal dialysis patients Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 20(Suppl 2): S178-S182
Makruasi, N.; Changsirikulchai, S.; Janma, J.; Rattanamongkolgul, S. 2016: Factors Related to Erythropoietin Hyporesponsiveness in Peritoneal Dialysis Patients with Anemia Journal of the Medical Association of Thailand 99(Suppl 8): S48-S52
Laupacis, A. 1991: A randomized double-blind study of recombinant human erythropoietin in anaemic hemodialysis patients. Canadian Erythropoietin Study Group Transplantation Proceedings 23(2): 1825-1826
Lai, P.C.; Wu, M.S.; Huang, J.Y.; Huang, C.C.; Leu, M.L. 1994: Efficacy of intravenous and subcutaneous erythropoietin in patients on hemodialysis and continuous ambulatory peritoneal dialysis Changgeng Yi Xue Za Zhi 17(2): 105-112
Fine, R.N.; Koch, V.H.; Boechat, M.I.; Lippe, B.H.; Nelson, P.A.; Fine, S.E.; Sherman, B.M. 1990: Recombinant human growth hormone (rhGH) treatment of children undergoing peritoneal dialysis Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 10(3): 209-214
Zelichowski, G.; Lubas, A.; Sienkiewicz, M.; Janusz, E.; Wańkowicz, Z. 2008: Treatment of renal anemia with intravenous erythropoietin in patients in the program of continuous ambulatory peritoneal dialysis Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 24(142): 312-315
Cueto-Manzano, A.M.; Rojas-Campos, E.; Martínez-Ramírez, H.éc.R.; Valera-González, I.; Medina, M.; Monteón, F.; Ruiz, N.; Becerra, M.; Palomeque, M.A.; Cortés-Sanabria, L. 2006: Can the inflammation markers of patients with high peritoneal permeability on continuous ambulatory peritoneal dialysis be reduced on nocturnal intermittent peritoneal dialysis? Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 26(3): 341-348
Adachi, Y.; Nakagawa, Y.; Nishio, A. 2006: In patients treated with peritoneal dialysis, icodextrin improves erythropoietin-resistant anemia through blockade of asialo receptors on hepatocytes Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis 22: 41-44
Sharples, E.J.; Varagunam, M.; Sinnott, P.J.; McCloskey, D.J.; Raftery, M.J.; Yaqoob, M.M. 2006: The effect of proinflammatory cytokine gene and angiotensin-converting enzyme polymorphisms on erythropoietin requirements in patients on continuous ambulatory peritoneal dialysis Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 26(1): 64-68
Urra, J.M.; de la Torre, M.; Alcazar, R.; Peces, R. 1997: Rapid method for detection of anti-recombinant human erythropoietin antibodies as a new form of erythropoietin resistance Clinical Chemistry 43(5): 848-849
Virón, B.éa.; Kolta, A.; Kiladjian, J.J.; Mignon, F.; Mayeux, P.; Casadevall, N. 2002: Antibodies against human recombinant erythropoietin: an unusual cause of erythropoietin resistance Nephrologie 23(1): 19-22
Kakuk, G.; Kárpáti, I.; Mátyus, J. 1990: Recombinant human erythropoietin in the therapy of anemia in hemodialyzed patients Orvosi Hetilap 131(43): 2365-2366; 2369-2371
Mohini, R. 1989: Clinical efficacy of recombinant human erythropoietin in hemodialysis patients Seminars in Nephrology 9(1 Suppl 1: 16-21